Eli Lilly (LLY)
(Delayed Data from NYSE)
$934.14 USD
-5.64 (-0.60%)
Updated Jul 11, 2024 04:00 PM ET
After-Market: $934.50 +0.36 (0.04%) 5:24 PM ET
3-Hold of 5 3
D Value B Growth A Momentum C VGM
Eli Lilly (LLY) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Downside to Average Price Target |
---|---|---|---|
$833.36 | $1,041.00 | $600.00 | -10.63% |
Price Target
Based on short-term price targets offered by 22 analysts, the average price target for Eli Lilly comes to $833.36. The forecasts range from a low of $600.00 to a high of $1,041.00. The average price target represents a decline of 10.63% from the last closing price of $932.50.
Analyst Price Targets (22)
Broker Rating
Eli Lilly currently has an average brokerage recommendation (ABR) of 1.20 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 22 brokerage firms. The current ABR compares to an ABR of 1.20 a month ago based on 22 recommendations.
Of the 22 recommendations deriving the current ABR, 19 are Strong Buy and one is Buy. Strong Buy and Buy respectively account for 86.36% and 4.55% of all recommendations. A month ago, Strong Buy made up 86.36%, while Buy represented 4.55%.
Broker Rating Breakdown
![Broker Rating Visualization](https://widget3.zacks.com/images/charts/bar/brokerage/bar/LLY.png)
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 19 | 19 | 19 | 19 | 19 |
Buy | 1 | 1 | 1 | 1 | 1 |
Hold | 2 | 2 | 2 | 2 | 2 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.20 | 1.20 | 1.20 | 1.20 | 1.20 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
7/2/2024 | Berenberg Bank | Kerry Holford | Strong Buy | Strong Buy |
7/1/2024 | Cantor Fitzgerald & Co | Louise Chen | Strong Buy | Strong Buy |
5/30/2024 | Wells Fargo Securities | Mohit Bansal | Strong Buy | Strong Buy |
5/16/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
5/14/2024 | Argus Research Corp. | David A Toung | Strong Buy | Strong Buy |
5/6/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
5/1/2024 | Truist Securities | Srikripa Devarakonda | Strong Buy | Strong Buy |
5/1/2024 | BMO Capital Markets | Evan Seigerman | Strong Buy | Strong Buy |
5/1/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
4/30/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
4/12/2024 | SVB Securities | David Risinger | Strong Buy | Strong Buy |
4/11/2024 | Goldman Sachs | Chris Shibutani | Hold | Hold |
4/2/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
4/2/2024 | Guggenheim Securities | Seamus Fernandez | Strong Buy | Strong Buy |
4/1/2024 | Cowen & Co. | Steve M Scala | Strong Buy | Strong Buy |
12/21/2023 | Daiwa America | Narumi Nakagiri | Not Available | Strong Buy |
10/20/2023 | UBS | Trung Huynh | Not Available | Strong Buy |
9/11/2023 | Not Identified | Not Identified | Not Available | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.20 |
ABR (Last week) | 1.20 |
# of Recs in ABR | 22 |
Average Target Price | $841.45 |
LT Growth Rate | 33.30% |
Industry | Large Cap Pharmaceuticals |
Industry Rank by ABR | 101 of 252 |
Current Quarter EPS Est: | 2.65 |